Targets › BTN3A1
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jun 2029.
Plays a role in T-cell activation and in the adaptive immune response. Regulates the proliferation of activated T-cells. (UniProt, O00481)
Open in Phaseline: the race on BTN3A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Chinese PLA General Hospital | Allogeneic TCR-enhanced Vδ2 T cell Injection Allogeneic genetically engineered Vδ2 T cells with enhanced BTN protein-binding moiety for | BTN3A1 | Phase 1 | Hematologic Malignancy | Jun 2029 |
Hematologic Malignancy (1)
mixed (1)
Chinese PLA General Hospital (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.